Melatonin protects against cisplatin-induced ovarian damage in mice via the MT1 receptor and antioxidant activity

Ricássio S Barberino1, Vanúzia G Menezes1, Anita E A S Ribeiro2

  • 1Nucleus of Biotechnology Applied to Ovarian Follicle Development, Federal University of São Francisco Valley - UNIVASF, Petrolina, Brazil.

Insights

Melatonin pretreatment protects against cisplatin-induced ovarian toxicity by preserving follicular morphology and reducing apoptosis. This protective effect is mediated by the MT1 receptor and melatonin's antioxidant properties.

Area of Science:

  • Reproductive toxicology
  • Pharmacology
  • Biochemistry

Background:

  • Cisplatin is a widely used chemotherapy agent with known ovarian toxicity.
  • Melatonin, a hormone with antioxidant and anti-apoptotic properties, may offer protection against cisplatin-induced damage.
  • The specific mechanisms, including receptor involvement and antioxidant stress pathways, require further elucidation.

Purpose of the Study:

  • To investigate the protective mechanisms of melatonin against cisplatin-induced ovarian toxicity.
  • To determine the role of melatonin receptors (MT1 and MT2) in mediating this protection.
  • To evaluate the contribution of antioxidant stress pathways to melatonin's ovarian protective effects.

Main Methods:

  • Mice were pretreated with varying doses of melatonin before cisplatin administration.
  • Pharmacological modulation of melatonin receptors was assessed using selective and non-selective antagonists.
  • Ovarian tissues were analyzed for histological changes, apoptosis markers (activated caspase-3, bcl-2), cell proliferation (PCNA), reactive oxygen species (ROS), glutathione (GSH), and mitochondrial activity.
  • MT1 receptor expression was confirmed via immunohistochemistry.

Main Results:

  • Melatonin pretreatment (20 mg/kg) preserved ovarian follicular morphology and cell proliferation.
  • Melatonin significantly reduced cisplatin-induced apoptosis, ROS production, and mitochondrial damage.
  • Melatonin increased GSH expression in ovarian tissues.
  • A non-selective MT1/MT2 receptor antagonist abolished melatonin's protective effects, while a selective MT2 antagonist did not.
  • MT1 receptor protein expression was confirmed in mouse ovaries.

Conclusions:

  • Pretreatment with 20 mg/kg melatonin effectively protects ovaries from cisplatin-induced toxicity.
  • The protective effects of melatonin are mediated through the MT1 receptor.
  • Melatonin's antioxidant properties play a crucial role in its ovarian cytoprotective activity against cisplatin.

Related Concept Videos